Blaze™ System couples imaged cIEF separations with MS mass analysis. It monitors multiple Critical Quality Attributes (CQAs) in intact biotherapeutic proteins in one 15-minute assay. For the first time, generate high-resolution mass spectra directly from your charge variant peaks.
Our patented microfluidic technology lets you monitor multiple CQAs in just 15 minutes. Imaged cIEF separation, electrospray ionization, and downstream MS detection are integrated into a single, seamless assay.
Intabio® develops transformative product quality analytical solutions that provide early product quality characterization for efficiency gains across all stages of development and manufacturing of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins.
Intabio, a Silicon Valley–based company that received funding from NCATS through the Small Business Innovation Research (SBIR) program, set out to create a solution that would quickly and accurately ...Read more » February 02, 2021
FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX, a global leader in life science analytical technologies, announced the closing of its acquisition of Intabio, Inc., a privately held company and the ...Read more » January 21, 2021
Webinar Description: In order to bring safe, effective protein therapeutics to market, in particular next generation molecules, biopharma development scientists need to analyze critical quality ...Register »